Our findings provide not only prognostic insight into future risk stratification but also a novel biomarker-guided therapeutic approach to targeting angiogenesis in aggressive myxofibrosarcomas which harbor the vulnerable PAK1/STAT5B/CSF2 proangiogenic axis. This evidence concerns the gene CSF2 and myxofibrosarcoma.